

Participating in vaccine research for COVID-19 in Senegal: trust and information

Authors:

Valéry Ridde ^{a,*}, Mouhamadou Faly Ba ^b, Ibrahima Gaye ^b, Amadou Ibra Diallo ^b, Emmanuel Bonnet ^c, Adama Faye ^b

^a CEPED, IRD-University of Paris, ERL INSERM SAGESUD, Paris, France; Institute of Health and Development, Cheikh Anta Diop University, Dakar, Senegal

^b Institute of Health and Development, Cheikh Anta Diop University, Dakar, Senegal

^c IRD (French Institute for Research on Sustainable Development) IRD, UMR 215 Prodig, Aubervilliers, France

* Corresponding author.

E-mail address: valery.ridde@ird.fr (V. Ridde)

Abstract

This research aims to understand the level and determinants of people's willingness to participate in a vaccine trial for COVID-19 in Senegal. We conducted a telephone survey among a marginal quota sample of 607 people over 18 years of age. Only 44.3% of the participants wanted to participate in a vaccine trial for COVID-19, with females intending to participate more than males. Participants who intended to be vaccinated against COVID-19 (OR = 6.48, 95% CI [4.12-10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (OR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to take part in the COVID-19 vaccine research. Confidence in the vaccine, health personnel, and government in the fight against the pandemic are key factors in intending to participate in vaccine research in Senegal.

Keywords: Vaccine; Research; Vaccine hesitancy; COVID-19; Senegal

1. Introduction

The arrival of the COVID-19 pandemic has not changed Africa's collective imagination and discourse on Africa as a medical and vaccine testing ground. Indeed, historians and other social scientists have long documented how Africa has been the site of biomedical research, whether for testing drugs or vaccines [1-5]. Social scientists have shown the need for a complex and nuanced view beyond the ethical challenges and power issues [2,4]. However, we are in the process of "*globalizing human subjects research*" [6] after the scientific imperialism of the Pasteur Institutes [7].

In francophone Africa, particularly in Senegal, the COVID-19 pandemic has opened a new window of opportunity for these debates. Contrary to what is imagined about infectious diseases, after Ebola [8,9] or Lassa [10], Africa was neither the first continent to be affected nor the one that, thus far, suffered the most consequences [11]. However, a televised interview with two French doctors set off the "*April Fool's prank*" on April 1st, 2020 [12]. In

a context where debates on the decolonisation of global health are numerous [13,14], Africans hear these two Frenchmen say that it is necessary to test the BCG vaccine for prevention in Africa against COVID-19. Academic reactions on the ethical issues this raises and reactions in Africa's (social) media will be numerous [12,15]. Rumours about Africa as a vaccine testing ground will, from then on, continue to grow significantly [16]. At the end of the 1970s in Senegal, the first vaccine trials against hepatitis B gave rise to numerous ethical debates [3]. The 2007 meningitis vaccine trial also gave rise to numerous controversies, showing the lack of journalist's scientific culture and an attempt at political instrumentalisation [17]. This story was brought back to the forefront by the national media in April 2020 with the French doctors' speech. Yet Africa is by far one of the continents where biomedical research is least carried out, with COVID-19 being no exception [18]. A May 2020 analysis shows that of the 1002 therapeutic clinical trials for COVID-19 worldwide, only 32 (3.2%) were conducted in Africa [19]. Of the hundreds of ongoing vaccine trials against COVID-19, only 16 are taking place in Africa as of mid-March 2021 (South Africa: 11; Kenya = 3; Egypt 1; Morocco 1¹).

However, like other continents [20], Africa needs to conduct research and trials to test drugs and vaccines against COVID-19 [21]. Not only is this essential to adapt biomedical products and vaccines to national contexts and populations, but countries now have research centres and ethics committees competent to carry out these trials under good ethical conditions [18]. Thus, in a context where vaccines are the common solution to fight against the COVID-19 pandemic and other epidemics to come, it is important to understand the willingness of Senegalese to participate in a vaccine trial. Qualitative research in Senegal has shown that Senegalese people do not wish to be "exploited" by such COVID-19 vaccine trials but noted an ambiguous relationship and significant ignorance about how biomedical research works [22]. Thus, the objective of this article is to understand the level and determinants of Senegal's population's willingness to participate in a COVID-19 vaccine trial.

2. Method

We conducted a cross-sectional, descriptive, and analytical study. We collected data from December 24, 2020, to January 16, 2021. We carried out the study on a sample of 607 people aged over 18 years. We used the marginal quota sampling strategy [23] to have a representative sample of the national population stratified by population weight by region, gender, and age group. Five female interviewers speaking six languages (French, Diola, Wolof, Sérère, Pulaar, Soninké) carried out data collection through a telephone survey. We used tablets equipped with Open Data Kit (ODK) software to administer the questionnaire.

The variables in our study were based on acceptability models [24,25]. They included socio-demographic characteristics (age, gender, education, region of residence, wealth tercile, chronic medical conditions), vaccination history, attitude towards the COVID-19 vaccine measured by five items in the form of a five-point Likert scale, intention to be vaccinated against COVID-19, fear of the coronavirus, concern for serious health

¹ <https://covid19.trackvaccines.org/trials-vaccines-by-country/>

consequences if infected by the coronavirus, trust in the government to fight the COVID-19 epidemic, willingness to participate in COVID-19 vaccine research, and reasons for refusing or agreeing to participate in this research.

We used R software version 4.0.3 for data analysis. We described the quantitative variables by the mean \pm standard deviation and the qualitative variables by their frequencies. Then, we used a Chi2 test to compare two qualitative variables and a student's t test a qualitative and a quantitative variable. Finally, we used multivariate logistic regression to determine the factors associated with the willingness of respondents to participate in COVID-19 vaccine research. All variables with p-values less than 0.25 in the comparisons were retained for the full model construction [26]. We used the stepwise top-down selection procedure to build a more parsimonious reduced model [27]. Significance was considered at a p-value < 0.05 .

3. Results

Women represented 39.7% of the respondents. In our study, 15.5% of the respondents reported having a chronic disease. The average confidence in the Senegalese government in the fight against the epidemic was $6.6/10 \pm 3.1$. 54.4% of respondents expressed the intention to be vaccinated. According to their statements, 44.3% of the participants would like to participate in vaccine research for COVID-19 if it took place (Appendix 1). Of these, 23.0% (62/269) explained this because they trusted the health workers (Figure 1). Of those who refused to participate in the research, 34.4% (116/337) expressed a lack of trust in vaccines, and 29.4% (99/337) perceived a lack of safety of the vaccine research (Figure 2).




Figure 1: Reasons for willingness to participate in COVID-19 vaccine research (N=269)




Figure 2: Reasons for refusing to participate in COVID-19 vaccine research (N=337)

The proportion of the men who agreed to participate in the COVID-19 vaccination research (38.5%) was significantly lower than that of the women (53.1%, $p = 0.001$) (Appendix 2).

The results of the multivariate analysis showed that participants who intended to be vaccinated against COVID-19 (OR = 6.48, 95% CI [4.12-10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (OR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to participate in COVID-19 vaccination research (Table 1). The other three factors positively associated with willingness to participate in COVID-19 vaccination research were being female (OR = 1.82, 95% CI [1.22-2.72]), having a positive attitude towards the vaccine (OR = 1.69, 95% CI [1.09, 2.62]), and having confidence in the Senegalese government to control the coronavirus epidemic (OR = 1.09, 95% CI [1.02, 1.16]).

Table 1: Results of the multivariate analysis

Characteristics	Scale model		
	OR	95% CI	p-value
Gender			
Male	1.00	- —	
Woman	1.82	1.22, 2.72	0.003

Attitude towards the vaccine			
Wrong	1.00	- —	
Positive	1.69	1.09, 2.62	0.019
I intend to be vaccinated against COVID-19			
No	1.00	- —	
Yes	6.48	4.12, 10.4	<0.001
Do you think that being infected with the coronavirus will have a significant impact on your health?			
No	1.00	- —	
Yes	2.34	1.57, 3.51	<0.001
Do you have confidence in the Senegalese government to fight the coronavirus epidemic?	1.09	1.02, 1.16	0.011

4. Discussion

The results of this research are important in the context of the many controversies surrounding various vaccines, including AstraZeneca's vaccine, which is at the heart of the COVAX initiative for Africa. As Senegal began administering the Sinopharm vaccine in early March 2021 and then its first doses of AstraZeneca, understanding people's perceptions of vaccine research is essential. Indeed, in a context where there are calls for the decolonisation of global health research and for more vaccine research to be conducted in Africa [13,18], obtaining the views of those affected is an essential ethical issue [28,29].

In the contemporary context of this study, it is not surprising that the most favourable factor for wanting to participate in COVID-19 vaccine research is having the intention to be vaccinated. It should be noted that we conducted this study before the vaccines arrived in Senegal. The study also shows that other factors related to the health of individuals affect the intention to participate in research, such as perceived health status, belief in the consequences of vaccination on health, and positive attitude towards vaccination. Indeed, several authors have pointed out the importance of the health status and risk perception

of the people concerned in the context of controlled human infection studies like experimental vaccines for COVID-19 [29].

It is not only individual factors that seem to influence the intention of study participants. The research confirms the importance of the notion of trust, which is an essential value for the effectiveness of health systems [30] and for the intention to adopt health-promoting behaviours. As with the acceptability of government measures to control COVID-19 [31] or the intention to be vaccinated against COVID-19 [32], trust is an important determinant of willingness to participate in research [20]. Research in the United States of America has shown how racialised history affects African Americans' trust in government and influenza vaccination [33]. COVID-19 was a reminder that democracy, health, and pandemic are interrelated [34]. In Senegal, this trust seems to be multifaceted since it is demanded not only for the vaccine product but also for the health personnel and the government. Trust was already at the centre of the relationship between researchers and the population during the hepatitis B vaccine trial in Senegal in the 1970s and 1980s [3]. These results seem logical in a global context where *fake news* is widespread about vaccines, where Africa has been the scene of numerous medical experimentation abuses [1,2], and where the current mistrust of the Senegalese state apparatus is significant, including in the context of the COVID-19 pandemic [35]. It is essential to restore or increase this multifaceted trust to improve the willingness of Senegalese to participate in vaccine research.

Funding

This research was conducted as part of the ARIACOV programme (Appui à la Riposte Africaine à l'épidémie de Covid-19), which receives funding from the French Development Agency through the "COVID-19 - Santé en commun" initiative.

Ethical approval

The study was approved by the National Ethics Committee for Health Research in Senegal (SEN/20/23).

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- [1] Chabrol F. Biomedicine, Public Health, and Citizenship in the Advent of Antiretrovirals in Botswana: The Advent of Antiretrovirals in Botswana. *Developing World Bioeth.* 2014;14: 75-82. doi:10.1111/dewb.12051
- [2] Lachenal G. *The drug that was supposed to save Africa: a pharmaceutical scandal in the colonies.* Paris: La Découverte; 2014.
- [3] Moulin AM, Chabrol F, Ouvrier A. Chapter 24. History of a vaccine like no other: the first steps of the hepatitis B vaccine in Senegal. In: Delaunay V, Desclaux A, Sokhna C, editors. *Niakhar, memories and perspectives.* IRD Éditions; 2018. pp. 489-510. doi:10.4000/books.irdeditions.31872
- [4] Koster W, Ndione AG, Adama M, Guindo I, Sow I, Diallo S, et al. An oral history of medical laboratory development in francophone West African countries. *African Journal of Laboratory Medicine.* 2021;10. doi:10.4102/ajlm.v10i1.1157
- [5] Worker A. *Medical research in Africa is a way for the West to test dangerous drugs. Misconceptions in global health.* University of Montreal Press; 2015. pp. 215-218. doi:10.4000/books.pum.3607
- [6] Petryna A. *Globalizing Human Subjects Research.* In: Petryna A, Lakoff A, Kleinman A, editors. *Global Pharmaceuticals.* Duke University Press; 2006. pp. 33-60. doi:10.1215/9780822387916-002
- [7] Moulin A-M. *Patriarchal Science: The Network of the Overseas Pasteur Institutes', Science and Empires Historical Studies about Scientific Development and European Expansion.* 1992. pp. 307–322.
- [8] Holding M, Ihekweazu C, Stuart JM, Oliver I. Learning from the Epidemiological Response to the 2014/15 Ebola Virus Disease Outbreak. *JEGH.* 2019 [cited 16 Feb 2020]. doi:10.2991/jegh.k.190808.002
- [9] Desclaux A, Badji D, Ndione AG, Sow K. Accepted monitoring or endured quarantine? Ebola contacts' perceptions in Senegal. *Social Science & Medicine.* 2017;178: 38-45. doi:10.1016/j.socscimed.2017.02.009
- [10] N'koué Sambieni E, Danko N, Ridde V. Lassa Virus Hemorrhagic Fever in Benin in 2014 in the context of Ebola: an epidemic revealing the weakness of the health system. *Anthropology and Health.* 2015 [cited 11 Jan 2017]. doi:10.4000/anthropologiesante.1772
- [11] Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. *The Lancet.* 2021; S0140673621006322. doi:10.1016/S0140-6736(21)00632-2
- [12] Tilley. COVID-19 across Africa: Colonial Hangovers, Racial Hierarchies, and Medical Histories. *Journal of West African History.* 2020;6: 155. doi:10.14321/jwestafrihist.6.2.0155
- [13] Ridde V, Ouedraogo S, Yaya S. Closing the diversity and inclusion gaps in francophone public health: a wake-up call. *BMJ Glob Health.* 2021;6: e005231. doi:10.1136/bmjgh-2021-005231
- [14] Büyüm AM, Kenney C, Koris A, Mkumba L, Raveendran Y. Decolonising global health: if not now, when? *BMJ Glob Health.* 2020;5: e003394. doi:10.1136/bmjgh-2020-003394
- [15] Hellmann F, Williams-Jones B, Garrafa V. COVID-19 and Moral Imperialism in Multinational Clinical Research. *Arch Med Res.* 2020;51: 572-573.

doi:10.1016/j.arcmed.2020.04.017

[16] Desclaux A. Covid-19: In West Africa, the vaccine is not the new magic bullet. 2021. Available: <https://vih.org/20210202/la-mondialisation-des-informations-et-la-fabrique-des-opinions-sur-les-traitements-du-covid-en-afrique/>

[17] Ouvrier M-A, Geissler W, Moulin A-M. Faire de la recherche médicale en Afrique: ethnographie d'un village-laboratoire sénégalais. IRD; Karthala. 2015.

[18] Kana MA, LaPorte R, Jaye A. Africa's contribution to the science of the COVID-19/SARS-CoV-2 pandemic. *BMJ Glob Health*. 2021;6: e004059. doi:10.1136/bmjgh-2020-004059

[19] Nkeck JR, Ndoadoumgue AL, Temgoua MN. COVID 19 pandemic, status of clinical trials in Africa on May 2020: need to reinforce. *Pan Afr Med J*. 2020;35. doi:10.11604/pamj.supp.2020.35.2.24349

[20] Wentzell E, Racila A-M. The social experience of participation in a COVID-19 vaccine trial: Subjects' motivations, others' concerns, and insights for vaccine promotion. *Vaccine*. 2021; S0264410X21003170. doi:10.1016/j.vaccine.2021.03.036

[21] Brotherton H, Usuf E, Nadjm B, Forrest K, Bojang K, Samateh AL, et al. Dexamethasone for COVID-19: data needed from randomised clinical trials in Africa. *The Lancet Global Health*. 2020;8: e1125-e1126. doi:10.1016/S2214-109X(20)30318-1

[22] Desclaux A. Acceptability of COVID vaccine in WCA. Dakar, Senegal; 2020.

[23] Deville J. A theory of quota surveys. *Survey Methodology, Statistics Canada*. 1991;12: 177–195.

[24] Huijts NMA, Molin EJE, Steg L. Psychological factors influencing sustainable energy technology acceptance: A review-based comprehensive framework. *Renewable and Sustainable Energy Reviews*. 2012;16: 525-531. doi:10.1016/j.rser.2011.08.018

[25] Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. *BMC Health Services Research*. 2017;17: 88. doi:10.1186/s12913-017-2031-8

[26] Hosmer DW, Lemeshow S. *Applied Logistic Regression*. 2nd Edition. New York, USA: Wiley-Interscience Publication; 2000.

[27] Zhang Z. Model building strategy for logistic regression: Purposeful selection. *Annals of Translational Medicine*. 2016;4: 4-10. doi:10.21037/atm.2016.02.15

[28] Kaljee L, Pach A, Stanton B. APPLIED ANTHROPOLOGY, VACCINE TRIALS AND FEASIBILITY STUDIES: INTERSECTIONS OF LOCAL KNOWLEDGE, BIOMEDICINE, AND POLICY. *Practicing Anthropology*. 2011;33: 39-43.

[29] Shah SK, Miller FG, Darton TC, Duenas D, Emerson C, Lynch HF, et al. Ethics of controlled human infection to address COVID-19. *Science*. 2020;368: 832-834. doi:10.1126/science.abc1076

[30] Gilson L. Trust and the development of health care as a social institution. *Soc Sci Med*. 2003;56: 1453–68.

[31] Guglielmi S, Dotti Sani GM, Molteni F, Biolcati F, Chiesi AM, Ladini R, et al. Public acceptability of containment measures during the COVID-19 pandemic in Italy: how institutional confidence and specific political support matter. *IJSSP*. 2020;ahead-of-print. doi:10.1108/IJSSP-07-2020-0342

[32] Latkin C, Dayton L, Yi G, Konstantopoulos A, Park J, Maulsby C, et al. COVID-19 vaccine intentions in the United States, a social-ecological framework. *Vaccine*. 2021;

S0264410X21002383. doi:10.1016/j.vaccine.2021.02.058

[33] Jamison AM, Quinn SC, Freimuth VS. "You don't trust a government vaccine": Narratives of institutional trust and influenza vaccination among African American and white adults. *Social Science & Medicine*. 2019;221: 87-94. doi:10.1016/j.socscimed.2018.12.020

[34] Bollyky TJ, Kickbusch I. Preparing democracies for pandemics. *BMJ*. 2020; m4088. doi:10.1136/bmj.m4088

[35] CIVICUS Monitor. National Civic Space Ratings. Johannesburg, South Africa; 2021. Available: <https://monitor.civicus.org>

Appendix 1: Distribution of respondents by characteristics (N=607)

Features	n (%)
Age:	
Under 25 years old	140 (23.1%)
25-59 years	407 (67.1%)
60+ years	60 (9.9%)
Sex:	
Male	366 (60.3%)
Woman	241 (39.7%)
Education:	
Not educated	253 (41.7%)
Educated	354 (58.3%)

Region:

Outside Dakar 412 (67.9%)

Dakar 195 (32.1%)

Tercile:

Poor 159 (26.2%)

Medium 131 (21.6%)

Rich 317 (52.2%)

Do you have a chronic disease for which you are being monitored?

No 513 (84.5%)

Yes 94 (15.5%)

Have you ever received a vaccine as an adult?

No 434 (71.5%)

Yes 173 (28.5%)

Attitude towards the vaccine:

Wrong 296 (48.8%)

Good 311 (51.2%)

I intend to get vaccinated against COVID-19:

No 277 (45.6%)

Yes 330 (54.4%)

Faced with the coronavirus, I am afraid:

No 177 (29.2%)

Yes 430 (70.8%)

Do you think that being infected with the coronavirus will have a significant impact on your health?

No 390 (64.3%)

Yes 217 (35.7%)

If there is research on the COVID-19 vaccine in Senegal and I am asked, I think I will participate:

No 338 (55.7%)

Yes 269 (44.3%)

Appendix 2: Distribution of respondents by characteristics and willingness to participate in COVID-19 vaccine research (N=607)

	N (% willing to participate in vaccine research)	p-value
Age:		0.773
Under 25 years old	140 (42.9%)	
25-59 years	407 (44.2%)	
60+ years	60 (48.3%)	
Sex:		0.001
Male	366 (38.5%)	
Woman	241 (53.1%)	
Education:		0.444
Not educated	253 (42.3%)	
Educated	354 (45.8%)	
Region:		0.737
Outside Dakar	412 (44.9%)	
Dakar	195 (43.1%)	
Tercile:		0.838
Poor	159 (44.0%)	
Medium	131 (46.6%)	
Rich	317 (43.5%)	

Do you have a chronic disease for which you are being monitored?		0.026
No	513 (42.3%)	
Yes	94 (55.3%)	
Have you ever received a vaccine as an adult?		0.032
No	434 (41.5%)	
Yes	173 (51.4%)	
Attitude towards the vaccine:		<0.001
Wrong	296 (25.0%)	
Good	311 (62.7%)	
I intend to get vaccinated against COVID-19:		<0.001
No	277 (18.4%)	
Yes	330 (66.1%)	
Faced with the coronavirus, I am afraid:		0.001
No	177 (33.9%)	
Yes	430 (48.6%)	
Do you think that being infected with the coronavirus will have a significant impact on your health?		<0.001
No	390 (36.4%)	
Yes	217 (58.5%)	

Do you have confidence in the government of Senegal to fight the coronavirus epidemic? ($\mu \pm \sigma$)	7.4 (2.6)	<0.001
---	------------------	------------------
